As Insurers Struggle With GLP-1 Drug Costs, Some Seek To Wean Patients Off

As Insurers Struggle With GLP-1 Drug Costs, Some Seek To Wean Patients Off

After losing 50 pounds on the injectable weight loss medication Zepbound, Kyra Wensley received a surprising letter from her pharmacy benefit manager in April. Her request for coverage had been denied, the letter said, because she’d had a body mass index of less than 35 when she started Zepbound. The 25-year-old who lives in New York had been taking Zepbound without incident for months, so she was confused: Why was her BMI, which had been around…